Retatrutide for cardiovascular diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Coronary Artery Disease, Peripheral Arterial Disease

Why this status

  1. 30 May 2023: Trial started, NCT05882045
  2. 31 May 2023: Trial registered, NCT05882045

The trials

NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

State
Completed
Phase
Phase 3
People
1,946 taking part
Started
30 May 2023
Primary completion
16 Apr 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2
Results
None posted
  1. 30 May 2023: Trial started
  2. 31 May 2023: Trial registered
  3. 14 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.